Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial
et al., Gut, doi:10.1136/gutjnl-2022-326952, NCT04724720 (history)
, Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind,.., Gut, doi:10.1136/gutjnl-2022-326952, NCT04724720
Small RCT with 27 famotidine and 28 placebo patients, showing improved recovery with treatment. Recovery was faster with treatment for 14 of 16 symptoms. There was no mortality or hospitalization. NCT04724720 (history).
|
risk of no recovery, 48.1% lower, RR 0.52, p = 0.23, treatment 5 of 27 (18.5%), control 10 of 28 (35.7%), NNT 5.8, day 28, ITT.
|
|
risk of no recovery, 43.2% lower, RR 0.57, p = 0.34, treatment 4 of 19 (21.1%), control 10 of 27 (37.0%), NNT 6.3, day 28, PP.
|
|
estimated time to 50% resolution, 28.1% lower, relative time 0.72, p < 0.01, treatment 27, control 28.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Brennan et al., 10 Feb 2022, Double Blind Randomized Controlled Trial, USA, peer-reviewed, 31 authors, study period January 2021 - April 2021, average treatment delay 4.0 days, trial NCT04724720 (history).
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.